The purpose of this study is to compare three finished products of PF-06954522 in terms of the uptake into the blood stream. This study is seeking participants who are: \- Healthy male or female participants aged 18 years or older. All participants in this study will receive PF-06954522 once by mouth. The participants may receive different tablets by mouth for PF-06954522. The study will compare experiences of people receiving three different products of PF-06954522. This will help understand how much PF-06954522 is taken up into the blood for each product given. Participants will take part into the study for about 77 days. During this time participants will have to stay onsite for 21 days. There will be one follow up (by telephone) study visit.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
23
Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth
Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.
Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, United States
Pfizer Clinical Research Unit
New Haven, Connecticut, United States
Area Under the Curve from time zero to extrapolated infinite time (AUCinf) of PF-06954522 to evaluate the relative bioavailability of three PF-06954522 formulations administered in the fasted state.
Time frame: 0 hours (pre-dose) to 72 hours (extrapolated to infinite time) post PF-06954522 dose in each period
Maximum Observed Plasma Concentration (Cmax) of PF-06954522 to evaluate the relative bioavailability of three PF-06954522 formulations administered in the fasted state.
Time frame: 0 hours (pre-dose) to 72 hours post PF-06954522 dose in each period
Number of Participants with Treatment-Emergent Adverse Events (AEs)
Time frame: From baseline up to 49 days after PF-06954522 dose in Period 1 Day 1
Number of Participants with Laboratory Test Abnormalities
Time frame: From baseline up to 72 hours after PF-06954522 dose in each period
Number of Participants with Summary of Post-Baseline Vital Signs Data
Time frame: From baseline up to 72 hours after PF-06954522 dose in each period
Number of Participants who met Defined Electrocardiogram (ECG) Criteria
Time frame: From baseline up to 72 hours after PF-06954522 dose in each period
Area Under the Curve from time zero to extrapolated infinite time (AUCinf) of PF-06954522 to evaluate the relative bioavailability of two PF-06954522 formulations administered in the fed state compared to fasted state.
Time frame: 0 hours (pre-dose) to 72 hours (extrapolated to infinite time) post PF-06954522 dose in each period
Maximum Observed Plasma Concentration (Cmax) of PF-06954522 to evaluate the relative bioavailability of two PF-06954522 formulations administered in the fed state compared to the fasted state.
Time frame: 0 hours (pre-dose) to 72 hours post PF-06954522 dose in each period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.